Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

(2011) Poulam M. Patel et al.   EUROPEAN JOURNAL OF CANCER

Trends in Dermatology: Melanoma Incidence

(2010) Darrell S. Rigel   ARCHIVES OF DERMATOLOGY

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

(2010) J C Hassel et al.   BRITISH JOURNAL OF CANCER

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

(2009) R F Kefford et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS